0.85Open0.70Pre Close55 Volume399 Open Interest20.00Strike Price5.81KTurnover108.21%IV8.03%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry1.25Extrinsic Value100Contract SizeAmericanOptions Type0.5043Delta0.1088Gamma14.85Leverage Ratio-0.0702Theta0.0026Rho7.49Eff Leverage0.0135Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet